Highest ROI Medications

GLP-1s do not usually fail because they are too weak.

They fail because the patient gets stuck in one of four loops:

The best medication stack is not about throwing drugs at every symptom.

It is about identifying the bottleneck and breaking the loop early.

---

First: The Baseline Problem

In adult Wegovy trials, nausea occurred in about 44% of patients versus 16% on placebo; vomiting occurred in 24% versus 6%; diarrhea in 30% versus 16%; constipation in 24% versus 11%; fatigue in 11% versus 5%; and dyspepsia in 9% versus 3%. Wegovy labeling also warns that nausea, vomiting, and diarrhea can cause dehydration and acute kidney injury in some cases.¹

For Zepbound, pooled obesity/overweight trials show nausea in 25–29% versus 8% placebo, diarrhea in 19–23% versus 8%, vomiting in 8–13% versus 2%, constipation in 11–17% versus 5%, dyspepsia in 9–10% versus 4%, and fatigue in 5–7% versus 3%. The label also notes that most nausea, vomiting, and diarrhea events occur during escalation and decrease over time.²

So the medication goal is not “treat side effects after they get bad.”

The goal is:

prevent side effects from becoming the reason the patient cannot dose, eat, hydrate, train, or continue therapy.

---

The BOTB Medication Stack

Dose Holding / Dose Reduction

Best for: almost every major side effect

ROI: highest overall

Evidence grade: strong consensus, label-consistent

The most underrated medication intervention is not adding another medication.

It is changing the GLP-1 exposure.

Expert consensus recommendations for GLP-1 GI adverse events explicitly support slower escalation, avoiding escalation while symptoms persist, extending the dose-escalation period, temporarily withholding therapy, stepping back to a previously tolerated dose, or using a lower maintenance dose when needed.³

This is the most important principle:

Do not treat a dose problem as a supplement problem.

If a patient is vomiting, unable to eat protein, severely constipated, dehydrated, or functionally impaired, the issue may not be “lack of ginger” or “lack of magnesium.”

The issue may be too much GLP-1 signal too quickly.

Practical use case

Dose holding makes sense when:

• nausea is persistent
• vomiting occurs
• constipation is uncontrolled
• reflux is worsening
• protein intake collapses
• hydration is poor
• weight loss is too rapid
• patient cannot train
• symptoms flare after each escalation

Quantified expectation

There is no clean RCT saying “dose holding reduces nausea by X%” because this is individualized clinical management. But Zepbound’s label states that nausea, vomiting, and diarrhea occur mostly during escalation and decrease over time, which supports the logic that slowing escalation gives adaptation time.²

BOTB verdict

Dose control is Tier 0. If the GLP-1 signal is too strong, everything else is downstream damage control.

---

Ondansetron

Best for: nausea/vomiting rescue

ROI: very high, short-term

Evidence grade: strong antiemetic evidence generally; indirect for GLP-1 nausea

Ondansetron is the cleanest “rescue medication” for nausea/vomiting.

Mechanistically, ondansetron blocks 5-HT3 receptors, which are central to nausea/vomiting pathways in the gut-brain axis. It is widely used for postoperative, chemotherapy-related, and medication-induced nausea/vomiting. Reviews of 5-HT3 antagonists support their antiemetic efficacy, although most data are not GLP-1-specific.⁴

Why it matters for GLP-1s:

GLP-1 nausea is not purely “stomach discomfort.” It likely involves delayed gastric emptying, vagal afferent signaling, brainstem nausea circuitry, and central appetite/reward pathways. Ondansetron does not fix delayed gastric emptying, but it can reduce the nausea/vomiting output enough to preserve hydration, food intake, and adherence.

Quantified expectation

Direct GLP-1-specific ondansetron trials are limited, so we should not claim it reduces semaglutide nausea from 44% to a precise number.

A practical estimate:

Scenario	Expected effect
mild nausea	may reduce symptom burden meaningfully
vomiting episodes	often useful as rescue
nausea from gastric overfilling	helps nausea signal, but does not empty the stomach
chronic daily nausea	should trigger dose reassessment, not just chronic ondansetron

Main downside

Ondansetron can worsen constipation, which is already a common GLP-1 side effect. It can also prolong QT interval in susceptible patients or at higher-risk dosing/settings.⁵

BOTB verdict

Ondansetron is high ROI for rescue nausea/vomiting, but dangerous as a lazy substitute for fixing dose, constipation, hydration, or meal structure.

---

Polyethylene Glycol / PEG 3350

Best for: constipation baseline control

ROI: extremely high

Evidence grade: strong guideline recommendation

If constipation is the bottleneck, PEG is probably the highest ROI medication-level option.

The 2023 joint AGA/ACG guideline for chronic idiopathic constipation makes a strong recommendation for polyethylene glycol based on moderate-quality evidence. The same guideline also strongly recommends linaclotide, plecanatide, and prucalopride after OTC treatments fail.⁶

Why PEG is so useful on GLP-1s:

GLP-1s slow gut motility. Food volume drops. Water intake often drops. Stool gets harder. Then constipation worsens reflux, bloating, nausea, and appetite suppression.

PEG breaks the mechanical loop.

Mechanism

PEG is an osmotic laxative. It holds water in the stool, improving softness and bowel movement frequency.

It is not a stimulant. It is not habit-forming in the same way people worry about stimulant laxatives. It is basically a stool-water tool.

Quantified expectation

GLP-1-specific PEG trials are lacking, but constipation guidelines support PEG as one of the best-evidenced OTC pharmacologic options.⁶

Practical expectation:

Problem	Expected PEG effect
hard stool	high
low stool frequency	high
bloating from stool backup	medium-high
nausea secondary to constipation	indirect but potentially meaningful
diarrhea-prone patient	bad fit

BOTB verdict

PEG is the most boring medication on the list and one of the most important. If constipation is driving the side-effect cascade, PEG can rescue the whole protocol.

---

Senna / Bisacodyl / Sodium Picosulfate

Best for: constipation rescue when transit is too slow

ROI: high but not universal

Evidence grade: guideline-supported for select use

Osmotic laxatives soften stool.

Stimulant laxatives move stool.

That difference matters.

The AGA/ACG constipation guideline strongly recommends sodium picosulfate and conditionally supports senna; stimulant laxatives are generally useful when stool is not moving despite hydration/fiber/osmotic support.⁶

Mechanism

Stimulant laxatives activate intestinal motility and secretion. For GLP-1 patients, this is relevant when slowed transit is the main problem.

Best-use phenotype

Use when:

• no bowel movement for several days
• PEG/fiber are not enough
• stool is not just hard but “not moving”
• bloating/pressure is worsening
• constipation is starting to trigger reflux/nausea

Avoid overuse if:

• diarrhea-prone
• cramping severe
• unclear abdominal pain
• possible obstruction
• severe dehydration

Quantified expectation

No direct GLP-1 RCT tells us exact reduction in constipation rate. But constipation baseline is high: 24% on Wegovy and 11–17% on Zepbound.¹ Stimulant laxatives are best thought of as “rescue transit agents,” not daily universal prophylaxis.

BOTB verdict

Senna/bisacodyl are not the foundation. They are the emergency brake release when GLP-1 transit slowing gets ahead of the patient.

---

Linaclotide / Plecanatide / Prucalopride

Best for: refractory constipation

ROI: very high in the right patient

Evidence grade: strong guideline recommendations after OTC failure

These are the prescription constipation weapons.

The AGA/ACG guideline strongly recommends linaclotide, plecanatide, and prucalopride for chronic idiopathic constipation when OTC agents fail.⁷

Why these matter for GLP-1s

Some patients do everything right:

• water
• fiber
• magnesium
• PEG
• walking
• meal timing

And still cannot move their bowels.

For those patients, staying constipated while escalating GLP-1s is a bad strategy. Refractory constipation can become the bottleneck that makes the entire medication feel intolerable.

Mechanisms

Medication	Mechanism
Linaclotide	guanylate cyclase-C agonist; increases intestinal fluid secretion and transit
Plecanatide	guanylate cyclase-C agonist; similar class
Prucalopride	5-HT4 agonist; prokinetic effect on colonic motility

Quantified expectation

In constipation guidelines, these are not fringe therapies; they are strongly recommended after OTC failure.⁶ Direct GLP-1-specific data are limited, so the proper claim is:

high expected benefit for refractory constipation phenotype, not universal prophylaxis.

BOTB verdict

For constipation-dominant GLP-1 intolerance, prescription constipation therapy may be more important than anti-nausea therapy because constipation can be the root cause of bloating, reflux, and nausea.

---

Famotidine / H2 Blockers

Best for: mild reflux, injection-week heartburn, nighttime acid symptoms

ROI: high for mild/intermittent GERD

Evidence grade: guideline-supported, less potent than PPIs

GLP-1 reflux often happens because delayed gastric emptying and increased gastric pressure make the upper-GI system less forgiving. Wegovy and Zepbound labels both list dyspepsia, eructation, GERD/reflux-like symptoms, abdominal distension, and related upper-GI effects as common adverse reactions.¹

Famotidine is useful when the problem is acid-related and intermittent.

Mechanism

Famotidine blocks histamine H2 receptors in the stomach, reducing acid secretion.

It does not fix delayed gastric emptying. It does not fix overeating on a slowed stomach. It reduces acid exposure.

Quantified expectation

Guidelines recognize H2 blockers as GERD therapies, but PPIs are generally more effective for healing erosive esophagitis and stronger acid suppression.⁸

BOTB verdict

Famotidine is the best low-friction medication for mild/intermittent reflux, especially if symptoms cluster around injection days or nighttime.

---

Proton Pump Inhibitors

Best for: persistent GERD, erosive symptoms, significant reflux/dyspepsia

ROI: high when reflux is true acid-driven GERD

Evidence grade: strong guideline support

PPIs are more powerful than H2 blockers for acid suppression.

The 2022 ACG GERD guideline recommends PPIs for GERD management, and PPIs are generally preferred over H2 blockers for healing erosive esophagitis.⁸

Why PPIs matter on GLP-1s

If a patient develops persistent reflux, they may start avoiding meals. That worsens protein intake, hydration, and fatigue. So treating reflux is not just comfort; it preserves the nutrition protocol.

Best-use phenotype

PPI makes more sense when:

• reflux is frequent
• heartburn is persistent
• dyspepsia is acid-like
• nighttime reflux is impairing sleep
• there is known GERD history
• H2 blocker is inadequate

Important caveat

If the core problem is food sitting in the stomach from delayed emptying, a PPI may reduce acid burn but not solve the mechanical pressure. That is why meal size, meal timing, fat load, constipation control, and dose pacing still matter.

BOTB verdict

PPIs are high ROI for true GERD, but they are not a cure for GLP-1-induced delayed gastric emptying. They treat acid, not stomach traffic.

---

Metoclopramide

Best for: severe nausea with suspected gastric-emptying/motility bottleneck

ROI: potentially high, but risk-limited

Evidence grade: guideline-supported for gastroparesis; requires caution

Metoclopramide is the most mechanistically relevant anti-nausea medication for GLP-1 intolerance because it is both antiemetic and prokinetic.

The ACG gastroparesis guideline supports metoclopramide for refractory gastroparesis symptoms, and summaries note it is the only FDA-approved medication for gastroparesis in the U.S.⁹

Why this is interesting for GLP-1s

GLP-1 drugs delay gastric emptying. If a patient’s nausea is driven by food retention, bloating, early satiety, and gastric pressure, then a pure antiemetic like ondansetron may treat the nausea signal without fixing the motility problem.

Metoclopramide can address both nausea and gastric motility.

The massive caveat

Metoclopramide has a boxed warning for tardive dyskinesia, a serious movement disorder that can be irreversible. FDA labeling warns that risk increases with treatment duration and cumulative dose and says treatment for longer than 12 weeks should generally be avoided except in rare cases where benefit outweighs risk.¹⁰

BOTB verdict

Metoclopramide is powerful but not casual. It belongs in clinician-supervised rescue territory, not casual GLP-1 wellness stacks.

---

Loperamide

Best for: acute watery diarrhea

ROI: high in the right scenario

Evidence grade: guideline-supported for acute watery diarrhea in adults

Diarrhea is not rare on GLP-1s: about 30% on Wegovy versus 16% placebo and 19–23% on Zepbound versus 8% placebo.¹

Loperamide is the classic antidiarrheal.

IDSA guidelines state that loperamide may be used in immunocompetent adults with acute watery diarrhea, but it should be avoided when inflammatory diarrhea, fever, dysentery, or toxic megacolon risk is suspected.¹¹

Mechanism

Loperamide slows intestinal motility through peripheral opioid receptor activity in the gut.

Practical risk

The issue is not that loperamide “doesn’t work.” It works.

The issue is using it in the wrong diarrhea phenotype.

If diarrhea is infectious, bloody, febrile, severe, or associated with significant abdominal pain, suppressing motility can be dangerous.

BOTB verdict

Loperamide is high ROI for uncomplicated watery diarrhea, but it is a bad idea if the diarrhea looks inflammatory, infectious, or severe.

---

Bismuth Subsalicylate

Best for: mild diarrhea, nausea-adjacent dyspepsia, travel/food-triggered GI upset

ROI: moderate-high

Evidence grade: guideline-supported in acute diarrhea contexts

Bismuth is less targeted than loperamide but sometimes more forgiving.

World Gastroenterology Organisation guidance lists bismuth subsalicylate or loperamide as symptom-treatment options in nondysenteric traveler’s diarrhea, with oral rehydration as the hydration foundation.¹²

Why it may fit GLP-1 patients

Bismuth can be useful when the patient has loose stool plus upper-GI discomfort, mild nausea, or dyspepsia. It is not a cure for GLP-1 delayed gastric emptying, but it can reduce some GI symptom burden.

Caveats

Avoid/caution with:

• aspirin allergy
• anticoagulants
• kidney disease
• pregnancy
• children/teens with viral illness
• black stool confusion
• salicylate sensitivity

BOTB verdict

Bismuth is a useful GI multitool, but ORS handles dehydration and loperamide is stronger for pure watery diarrhea.

---

Ursodiol

Best for: gallstone prevention in rapid weight loss / high-risk patients

ROI: niche but potentially very high

Evidence grade: good in rapid weight-loss/bariatric settings; indirect for GLP-1s

This is the most interesting “under-discussed” medication.

Rapid weight loss increases gallstone risk. GLP-1 labels also warn about acute gallbladder disease, including cholelithiasis and cholecystitis. Wegovy labeling reports acute gallbladder disease events and notes that substantial or rapid weight loss can increase gallstone risk.¹

Ursodiol, or ursodeoxycholic acid, has evidence for preventing gallstones after rapid weight loss, especially in bariatric surgery populations. A multicenter randomized placebo-controlled trial found 600 mg/day ursodiol effective for gallstone prophylaxis after gastric bypass-induced rapid weight loss, and meta-analyses report reduced gallstone formation after bariatric procedures.¹³

Why this matters for GLP-1s

GLP-1 patients can now lose bariatric-surgery-scale weight without surgery. That makes gallstone prevention newly relevant.

But this is important:

Ursodiol is not standard for every GLP-1 user.

It is a high-risk phenotype medication.

Best-use phenotype

Consider discussing with a clinician if:

• very rapid weight loss
• history of gallstones
• intact gallbladder
• very low-fat intake
• large expected weight loss
• biliary colic symptoms
• bariatric-like weight loss trajectory

Quantified expectation

In bariatric/rapid-weight-loss settings, ursodiol has shown meaningful gallstone prevention, with 600 mg/day commonly identified as effective in older RCT evidence.¹³ However, direct GLP-1-specific ursodiol prevention trials are not established, so the correct framing is:

highly plausible for selected high-risk rapid-loss patients, not a universal GLP-1 add-on.

BOTB verdict

Ursodiol may become one of the most underrated GLP-1-adjacent medications for rapid losers, but it should be targeted, not casually added.

---

What Not to Overuse

Chronic ondansetron without fixing constipation

Ondansetron can help nausea but may worsen constipation. If constipation is already driving nausea, chronic ondansetron can create a trap: nausea improves temporarily while the constipation loop gets worse. QT risk also matters in susceptible patients.⁵

Metoclopramide as a casual anti-nausea drug

Metoclopramide is mechanistically attractive but risk-limited because of tardive dyskinesia warnings. FDA labeling advises avoiding treatment longer than 12 weeks except rare cases where benefit outweighs risk.¹⁴

PPIs for every upper-GI symptom

PPIs treat acid. They do not directly fix delayed gastric emptying, constipation, overeating, high-fat meals, or dose escalation intolerance. GERD guidelines support PPIs for GERD, but the mechanism has to match the symptom.⁸

Loperamide in dangerous diarrhea

Loperamide can be used in immunocompetent adults with acute watery diarrhea, but guidelines caution against use when inflammatory diarrhea, fever, or toxic megacolon risk is suspected.¹¹

---

Quantitative Medication Map

Side effect	Baseline rate	Highest ROI medication options	Expected practical effect
Nausea	Wegovy ~44%; Zepbound 25–29%	dose hold/reduction, ondansetron, metoclopramide if motility-driven/severe	ondansetron may rescue nausea/vomiting; dose control prevents recurrence
Vomiting	Wegovy ~24%; Zepbound 8–13%	ondansetron, ORS/fluids, dose hold, metoclopramide in select cases	reduce vomiting burden; prevent dehydration
Constipation	Wegovy ~24%; Zepbound 11–17%	PEG, senna/bisacodyl, linaclotide/plecanatide/prucalopride	PEG strongly guideline-supported; prescription agents for refractory cases
Diarrhea	Wegovy ~30%; Zepbound 19–23%	ORS, loperamide, bismuth	loperamide useful for uncomplicated watery diarrhea
GERD/dyspepsia	Wegovy dyspepsia ~9%; Zepbound 9–10%	famotidine, PPI	acid symptom reduction; does not fix delayed emptying
Gallstones	uncommon but clinically serious	ursodiol in high-risk rapid-loss phenotype	strong rapid-weight-loss/bariatric evidence; GLP-1 extrapolation
Lean mass loss	~25% of weight lost in tirzepatide body-comp data	no routine medication; preserve via dosing, nutrition, resistance training; investigational myostatin drugs	medication gap remains unsolved

Sources: Wegovy/Zepbound labels, AGA/ACG constipation guideline, ACG GERD and gastroparesis guidelines, tirzepatide body-composition data.¹

---

Final BOTB Ranking

Tier 0: The Master Lever

Dose hold / slower escalation / dose reduction

Best for: nausea, vomiting, constipation, reflux, under-eating, fatigue Why: most side effects are exposure-sensitive, especially during escalation.³

---

Tier 1: Highest ROI Medications

PEG 3350

Best for: constipation baseline control Why: strongly recommended by AGA/ACG constipation guideline.⁶

Ondansetron

Best for: nausea/vomiting rescue Why: strong antiemetic class, especially useful when nausea threatens hydration/intake; watch constipation/QT.⁴

Famotidine or PPI

Best for: acid reflux/GERD/dyspepsia phenotype Why: acid suppression can preserve sleep, meals, and adherence; PPIs are stronger for GERD/esophagitis.⁸

Loperamide

Best for: acute uncomplicated watery diarrhea Why: effective motility suppression when diarrhea is non-bloody/non-febrile.¹¹

---

Tier 2: High ROI in Specific Phenotypes

Senna / bisacodyl / sodium picosulfate

Best for: constipation rescue when stool is not moving Why: transit support when osmotic agents are not enough.⁶

Linaclotide / plecanatide / prucalopride

Best for: refractory constipation Why: strongly guideline-supported after OTC failure.⁷

Metoclopramide

Best for: severe motility-driven nausea/gastroparesis-like symptoms Why: antiemetic + prokinetic, but boxed-warning risk limits casual use.¹⁵

Ursodiol

Best for: high-risk rapid weight loss with gallstone concern Why: rapid-weight-loss/bariatric evidence; GLP-1-specific use is extrapolated.¹³

Bismuth subsalicylate

Best for: mild diarrhea/dyspepsia GI upset Why: useful GI multitool; not as targeted as loperamide or acid suppression.¹²

---

The Actual Medication Architecture

The cleanest medication strategy is not:

GLP-1 + anti-nausea med + laxative + PPI forever.

The better strategy is:

1. Control exposure first Slow escalation, hold dose, or reduce dose if the GLP-1 signal is overwhelming.

2. Prevent constipation early PEG/fiber/magnesium first; prescription constipation meds if refractory.

3. Use nausea rescue intelligently Ondansetron is useful, but do not let it hide constipation or overexposure.

4. Treat reflux according to mechanism H2/PPI if acid-driven; meal size/dose/constipation if pressure-driven.

5. Protect hydration during vomiting/diarrhea ORS/fluids first; loperamide only if diarrhea is uncomplicated and watery.

6. Consider gallbladder prevention only in high-risk rapid losers Ursodiol is interesting, but not universal.

---

Most Important to Remember

The highest ROI medication is often not a new medication.

It is a smarter GLP-1 dose.

After that, the best add-ons are bottleneck-specific:

PEG for constipation. Ondansetron for nausea/vomiting rescue. Famotidine/PPI for acid reflux. Loperamide for uncomplicated watery diarrhea. Prescription constipation agents for refractory cases. Metoclopramide only when motility-driven symptoms are severe enough to justify risk. Ursodiol only when rapid weight loss makes gallbladder risk worth discussing.

The goal is not to medicate every side effect.

The goal is to keep the patient inside the therapeutic window:

enough GLP-1 signal to lose fat and improve metabolic health, but not so much collateral damage that they cannot eat, hydrate, train, poop, sleep, or continue.

Related articles

1. Why Optimize?
2. Highest ROI Supplements
3. Dosing Protocols (Core Theory Revisited)